CDH2 and cancer: Recent studies have reported that N‐cadherin‐targeted melanin nanoparticles and photothermal treatment are promising strategies to regulate phenotypic switching of endothelial and cancer cells.[36, 37, 38] Additionally, zeolitic imidazolate framework‐8 nanoparticles have been reported to directly alter VSMC actin organization and contractility.[39] Future studies should explore whether these novel nanoparticles and photothermal treatments could similarly regulate VSMC phenotypic switching to prevent postinjury restenosis and treat atherosclerosis.